Format
Sort by

Send to

Choose Destination

Search results

Items: 1 to 20 of 99

1.

A multifunctional GH39 glycoside hydrolase from the anaerobic gut fungus Orpinomyces sp. strain C1A.

Morrison JM, Elshahed MS, Youssef N.

PeerJ. 2016 Aug 3;4:e2289. doi: 10.7717/peerj.2289. eCollection 2016.

2.
3.

Growth and physiology of Clostridium perfringens wild-type and ΔazoC knockout: an azo dye exposure study.

Morrison JM, John GH.

Microbiology. 2016 Feb;162(2):330-8. doi: 10.1099/mic.0.000212. Epub 2015 Nov 13.

PMID:
26566621
4.

Bone Disease in the Common Marmoset: Radiographic and Histological Findings.

Olson EJ, Shaw GC, Hutchinson EK, Schultz-Darken N, Bolton ID, Parker JB, Morrison JM, Baxter VK, Pate KA, Mankowski JL, Carlson CS.

Vet Pathol. 2015 Sep;52(5):883-93. doi: 10.1177/0300985815589354. Epub 2015 Jun 15.

PMID:
26077785
5.

Non-classical azoreductase secretion in Clostridium perfringens in response to sulfonated azo dye exposure.

Morrison JM, John GH.

Anaerobe. 2015 Aug;34:34-43. doi: 10.1016/j.anaerobe.2015.04.007. Epub 2015 Apr 14.

PMID:
25881497
6.

Hiding in Plain Sight: Interplay between Staphylococcal Biofilms and Host Immunity.

Scherr TD, Heim CE, Morrison JM, Kielian T.

Front Immunol. 2014 Feb 5;5:37. doi: 10.3389/fimmu.2014.00037. eCollection 2014. Review.

7.

The non-enzymatic reduction of azo dyes by flavin and nicotinamide cofactors under varying conditions.

Morrison JM, John GH.

Anaerobe. 2013 Oct;23:87-96. doi: 10.1016/j.anaerobe.2013.07.005. Epub 2013 Jul 26.

PMID:
23891960
8.

A randomised controlled trial to evaluate both the role and the optimal fractionation of radiotherapy in the conservative management of early breast cancer.

Spooner D, Stocken DD, Jordan S, Bathers S, Dunn JA, Jevons C, Dodson L, Morrison JM, Oates GD, Grieve RJ; West Midlands Oncology Breast Cancer Group.

Clin Oncol (R Coll Radiol). 2012 Dec;24(10):697-706. doi: 10.1016/j.clon.2012.08.003. Epub 2012 Oct 1.

PMID:
23036277
9.

The staphylococcal accessory regulator, SarA, is an RNA-binding protein that modulates the mRNA turnover properties of late-exponential and stationary phase Staphylococcus aureus cells.

Morrison JM, Anderson KL, Beenken KE, Smeltzer MS, Dunman PM.

Front Cell Infect Microbiol. 2012 Mar 8;2:26. doi: 10.3389/fcimb.2012.00026. eCollection 2012.

10.

(UO2)2[UO4(trz)2](OH)2: a U(VI) coordination intermediate between a tetraoxido core and a uranyl ion with cation-cation interactions.

Weng Z, Wang S, Ling J, Morrison JM, Burns PC.

Inorg Chem. 2012 Jul 2;51(13):7185-91. doi: 10.1021/ic300240s. Epub 2012 Jun 11.

PMID:
22686331
11.

Characterization of SSR42, a novel virulence factor regulatory RNA that contributes to the pathogenesis of a Staphylococcus aureus USA300 representative.

Morrison JM, Miller EW, Benson MA, Alonzo F 3rd, Yoong P, Torres VJ, Hinrichs SH, Dunman PM.

J Bacteriol. 2012 Jun;194(11):2924-38. doi: 10.1128/JB.06708-11. Epub 2012 Apr 6.

12.

Identification, Isolation and characterization of a novel azoreductase from Clostridium perfringens.

Morrison JM, Wright CM, John GH.

Anaerobe. 2012 Apr;18(2):229-34. doi: 10.1016/j.anaerobe.2011.12.006. Epub 2011 Dec 13.

PMID:
22182443
13.

The modulation of Staphylococcus aureus mRNA turnover.

Morrison JM, Dunman PM.

Future Microbiol. 2011 Oct;6(10):1141-50. doi: 10.2217/fmb.11.102.

14.

Small molecule inhibitors of Staphylococcus aureus RnpA alter cellular mRNA turnover, exhibit antimicrobial activity, and attenuate pathogenesis.

Olson PD, Kuechenmeister LJ, Anderson KL, Daily S, Beenken KE, Roux CM, Reniere ML, Lewis TL, Weiss WJ, Pulse M, Nguyen P, Simecka JW, Morrison JM, Sayood K, Asojo OA, Smeltzer MS, Skaar EP, Dunman PM.

PLoS Pathog. 2011 Feb 10;7(2):e1001287. doi: 10.1371/journal.ppat.1001287.

15.

U(VI) uranyl cation-cation interactions in framework germanates.

Morrison JM, Moore-Shay LJ, Burns PC.

Inorg Chem. 2011 Mar 21;50(6):2272-7. doi: 10.1021/ic1019444. Epub 2011 Feb 3.

PMID:
21291192
16.

Overview of the randomized trials of radiotherapy in ductal carcinoma in situ of the breast.

Early Breast Cancer Trialists' Collaborative Group (EBCTCG), Correa C, McGale P, Taylor C, Wang Y, Clarke M, Davies C, Peto R, Bijker N, Solin L, Darby S.

J Natl Cancer Inst Monogr. 2010;2010(41):162-77. doi: 10.1093/jncimonographs/lgq039. Review.

PMID:
20956824
17.

Syntheses, structures, and characterization of open-framework uranyl germanates.

Ling J, Morrison JM, Ward M, Poinsatte-Jones K, Burns PC.

Inorg Chem. 2010 Aug 2;49(15):7123-8. doi: 10.1021/ic1010242.

PMID:
20608708
18.

Inactivation of phospholipase D diminishes Acinetobacter baumannii pathogenesis.

Jacobs AC, Hood I, Boyd KL, Olson PD, Morrison JM, Carson S, Sayood K, Iwen PC, Skaar EP, Dunman PM.

Infect Immun. 2010 May;78(5):1952-62. doi: 10.1128/IAI.00889-09. Epub 2010 Mar 1.

19.

A randomised controlled trial of the use of aciclovir and/or prednisolone for the early treatment of Bell's palsy: the BELLS study.

Sullivan FM, Swan IR, Donnan PT, Morrison JM, Smith BH, McKinstry B, Davenport RJ, Vale LD, Clarkson JE, Hernández R, Stewart K, Hammersley V, Hayavi S, McAteer A, Gray D, Daly F.

Health Technol Assess. 2009 Oct;13(47):iii-iv, ix-xi 1-130. doi: 10.3310/hta13470.

20.

Bell's palsy: new evidence provides a definitive drug therapy strategy.

Davenport RJ, McKinstry B, Morrison JM, Smith BH, Swan IR, Sullivan F.

Br J Gen Pract. 2009 Aug;59(565):569-70. doi: 10.3399/bjgp09X453765. No abstract available.

Items per page

Supplemental Content

Loading ...
Write to the Help Desk